Strata finalizes purchase of Keystone Perfusion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 16 2025
0mins
Acquisition Announcement: Strata Critical Medical (SRTA) has acquired Keystone Perfusion Services for $124 million, primarily in cash, marking a significant move in the organ recovery and transplant industry.
Financial Details: The deal includes a potential earn-out of up to $23 million for Keystone's management based on future gross profit growth, with a focus on maintaining key personnel for at least three years post-acquisition.
Analyst Views on SRTA
Wall Street analysts forecast SRTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRTA is 9.63 USD with a low forecast of 8.00 USD and a high forecast of 11.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.660
Low
8.00
Averages
9.63
High
11.25
Current: 5.660
Low
8.00
Averages
9.63
High
11.25
About SRTA
Strata Critical Medical, Inc. provides time-critical logistics solutions and specialized medical services to healthcare providers across the United States, expanding its portfolio of services through acquisition and organic growth. The Company focuses on the contractual and macro-non-correlated marketplaces for organ logistics and other medical services. Its subsidiary, Trinity Medical Solutions (Trinity), is engaged in the air and ground transportation of human organs for transplant, leveraging its asset-light platform to deliver logistics solutions to its customers across the United States. Trinity provides Organ Placement Services (TOPS) and Logistics Solutions for Transplant Centers and organ procurement organizations (OPOS). The Company also offers a full-service organ transplant service provider offering surgical recovery, NRP services, air and ground logistics and organ placement services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
